IMDX (Insight Molecular Diagnostics) ROCE %: -81.08% (As of Mar. 2026)

What is Insight Molecular Diagnostics ROCE %?

Insight Molecular Diagnostics IMDX +2.12% 49 ROCE % is -81.08% as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Insight Molecular Diagnostics's annualized ROCE % for the quarter that ended in Mar. 2026 was -81.08%.

Insight Molecular Diagnostics (NAS:IMDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Insight Molecular Diagnostics ROCE % Related Terms

Insight Molecular Diagnostics ROCE % Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics ROCE % Chart

Insight Molecular Diagnostics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-54.89

-15.88

-31.86

-126.86

-241.58

Insight Molecular Diagnostics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-67.70	-82.22	-108.06	-367.17	-81.08

49GF Score

Insight Molecular Diagnostics Inc IMDX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Insight Molecular Diagnostics ROCE % Calculation

Insight Molecular Diagnostics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-50.113	/	( ( (35.081 - 7.275)	+	(25.756 - 12.075) )	/ 2 )
	=	-50.113	/	( (27.806	+	13.681)	/ 2 )
	=	-50.113	/	20.7435
	=	-241.58 %

Insight Molecular Diagnostics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-17.068	/	( ( (25.756 - 12.075)	+	(40.427 - 12.005) )	/ 2 )
	=	-17.068	/	( ( 13.681	+	28.422 )	/ 2 )
	=	-17.068	/	21.0515
	=	-81.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -81.08% mean?

Insight Molecular Diagnostics (IMDX) has a ROCE % of -81.08% as of Mar. 2026.

Is Insight Molecular Diagnostics' ROCE % too high?

Insight Molecular Diagnostics' current ROCE % is -81.08%. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Insight Molecular Diagnostics' ROCE % compare to BDSX and XGN?

Insight Molecular Diagnostics' ROCE % of -81.08% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Diagnostics & Research company?

A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Insight Molecular Diagnostics's current ROCE % is -81.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Insight Molecular Diagnostics stock overvalued right now?

Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.54 — trading 339.3% above its estimated fair value. The current ROCE % is -81.08%. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current ROCE % is -81.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.54 is trading 339.3% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

ROCE %: -81.08%
GF Value™: $1.26 vs. price of $5.54 (339.3% above fair value)
GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies BDSX XGN FONR BNR QUCY IDXG PRE PRPO MDXH BIOQ TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN

Other Exchanges 0KCC:UK 7OC0:Germany

Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217

Website https://www.imdxinc.com

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

49GF Score

Get the complete analysis for IMDX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.54

Price

$1.26

GF Value

View IMDX Analysis

See ROCE % data for all stocks →